SR One
VC Fund
Cambridge, United States
SR One is a VC fund in Cambridge focused on Biotechnology and Health Care. SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
- Total investments:
- 199
- Last investment:
- Lead investor:
- 33%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries SR One invests in
Stages SR One invests in
Countries SR One invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $3.7M–$100M
- Series B
- $15M–$114M
- Series C
- $22M–$175M
Investment Focus
Industry
- Biotechnology 79 (40%)
- Health Care 58 (29%)
- Therapeutics 39 (20%)
- Medical 35 (18%)
- Pharmaceutical 29 (15%)
Stage
- Series A 49 (25%)
- Series B 44 (22%)
- Series C 33 (17%)
- Series D 13 (7%)
- Funding Round 10 (5%)
Country
- United States 74 (37%)
- United Kingdom 11 (6%)
- Canada 3 (2%)
- Switzerland 3 (2%)
- Israel 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jill Carroll
Partner
|
Partner | Total investments: 10 | Find email | |
Simeon George
Chief Executive Officer
|
Chief Executive Officer | Total investments: 24 | Find email | |
Christopher Y. Chai
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Iqbal Mufti
Partner
|
Partner | Total investments: 3 | Find email | |
Jens Eckstein
President
|
President | Total investments: 18 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $130M / Series B / Jul 22, 2026 | ||
| We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M / Series D / Jul 07, 2026 | ||
| Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M / Series B / May 04, 2026 | ||
| Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils. | $87.1M / Series A / Mar 24, 2026 | ||
| Jixing Pharmaceuticals develops innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases. | $287M / Series D / Jan 22, 2026 | ||
| AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions. | $200M / Series A / Jan 09, 2026 | ||
| Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis. | $50M / Series A / Jan 07, 2026 | ||
| Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovativemethods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies. | $100M / Series A / Dec 17, 2025 | ||
| Veradermics is a dermatology-focused biopharmaceutical company that develops treatments for common skin and hair conditions. Its lead drug candidate, VDPHL01, is an extended-release oral minoxidil being tested in Phase 3 clinical trials for pattern hair loss in both women and men. The company also has pipeline programs targeting conditions such ascommon warts, molluscum contagiosum, and atopic dermatitis. | $150M / Series C / Oct 16, 2025 | ||
| Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylatingenzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis. | $13.3M / Venture - Series Unknown / Oct 15, 2025 | ||
| See all 199 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SR One invest in?
SR One invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 199 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SR One's check size?
SR One typically joins rounds of $3.7M–$100M at Series A, $15M–$114M at Series B and $22M–$175M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SR One participates in.
How do I contact SR One?
Public channels for SR One include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SR One?
The team at SR One includes Jill Carroll (Partner), Simeon George (Chief Executive Officer) and Christopher Y. Chai (Venture Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
